HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.

Abstract
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved difficult to devise a nondopaminergic therapy with significant antiparkinsonian efficacy when administered as monotherapy. Overactivity of the striatolateral pallidal pathway, the "indirect" striatal output pathway, is thought be responsible for the generation of parkinsonian symptoms. Indeed, it has been suggested that selective reduction in the activity of the "indirect" pathway may be achieved by blockade of NR2B-containing NMDA receptors. In the present study, we demonstrate that selective blockade of NR2B-containing NMDA receptors with the polyamine antagonists ifenprodil and eliprodil causes a significant increase in locomotor activity in the reserpine-treated rat model of Parkinson's disease (30 mg/kg ifenprodil, 221.2 +/- 54 mobile counts compared to vehicle, 19.6 +/- 6.87, P < 0.001). Additionally, we show that, subsequent to dopamine depletion, the ability of ifenprodil to bind to the polyamine site and inhibit binding of the NMDA channel blocker [3H] MK-801 is increased fourfold (IC50 3.7 +/- 0.4 microM compared to vehicle, IC50 14.3 +/- 2.34 microM, P < 0.01). We suggest that ifenprodil selectively targets the polyamine site on overactive NR2B-containing NMDA receptors. Thus, we propose that NR2B-selective NMDA receptor antagonists may prove useful in the treatment of Parkinson's disease.
AuthorsJ E Nash, M P Hill, J M Brotchie
JournalExperimental neurology (Exp Neurol) Vol. 155 Issue 1 Pg. 42-8 (Jan 1999) ISSN: 0014-4886 [Print] United States
PMID9918703 (Publication Type: Journal Article)
CopyrightCopyright 1999 Academic Press.
Chemical References
  • Antiparkinson Agents
  • Excitatory Amino Acid Antagonists
  • Piperidines
  • Receptors, N-Methyl-D-Aspartate
  • Dizocilpine Maleate
  • Reserpine
  • ifenprodil
  • eliprodil
Topics
  • Animals
  • Antiparkinson Agents (pharmacology)
  • Binding, Competitive (drug effects)
  • Corpus Striatum (metabolism)
  • Dizocilpine Maleate (metabolism)
  • Dose-Response Relationship, Drug
  • Excitatory Amino Acid Antagonists (metabolism, pharmacology)
  • Male
  • Parkinson Disease, Secondary (chemically induced, metabolism)
  • Piperidines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
  • Reserpine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: